File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma

TitleClinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma
Authors
Kwok, WCCheong, TFChiang, KYHo, JCMLam, CLDIp, MSMTam, CCT
Issue Date2022
Citation
Asia-Pacific Journal of Clinical Oncology, 2022 How to Cite?
DOI: http://dx.doi.org/10.1111/ajco.13658
Persistent Identifierhttp://hdl.handle.net/10722/316261
ISI Accession Number ID
WOS:000783963900001

 

DC FieldValueLanguage
dc.contributor.authorKwok, WC-
dc.contributor.authorCheong, TF-
dc.contributor.authorChiang, KY-
dc.contributor.authorHo, JCM-
dc.contributor.authorLam, CLD-
dc.contributor.authorIp, MSM-
dc.contributor.authorTam, CCT-
dc.date.accessioned2022-09-02T06:08:22Z-
dc.date.available2022-09-02T06:08:22Z-
dc.date.issued2022-
dc.identifier.citationAsia-Pacific Journal of Clinical Oncology, 2022-
dc.identifier.urihttp://hdl.handle.net/10722/316261-
dc.languageeng-
dc.relation.ispartofAsia-Pacific Journal of Clinical Oncology-
dc.titleClinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma-
dc.typeArticle-
dc.identifier.emailKwok, WC: kwokwch@hku.hk-
dc.identifier.emailHo, JCM: jhocm@hku.hk-
dc.identifier.emailLam, CLD: dcllam@hku.hk-
dc.identifier.emailIp, MSM: msmip@hku.hk-
dc.identifier.authorityKwok, WC=rp02966-
dc.identifier.authorityHo, JCM=rp00258-
dc.identifier.authorityLam, CLD=rp01345-
dc.identifier.authorityIp, MSM=rp00347-
dc.identifier.doi10.1111/ajco.13658-
dc.identifier.hkuros336373-
dc.identifier.isiWOS:000783963900001-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats